The impact of the chromatin binding DEK protein in hematopoiesis and acute myeloid leukemia. Experimental Hematology. 2023; 123:18-27.
.Drug resistance mechanisms create targetable proteostatic vulnerabilities in Her2+ breast cancers. PloS one. 2022; 17:e0256788.
.Novel molecular mechanisms in Alzheimer's disease: The potential role of DEK in disease pathogenesis. Frontiers in Aging Neuroscience. 2022; 14:1018180.
.In silico gene expression and pathway analysis of DEK in the human brain across the lifespan. European Journal of Neuroscience. 2022; 56:4720-4743.
.Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Leukemia. 2022; 36:637-647.
.Defective transcription elongation in human cancers imposes targetable proteotoxic vulnerability. Translational Oncology. 2022; 16:101323.
.Loss of DEK Expression Induces Alzheimer's Disease Phenotypes in Differentiated SH-SY5Y Cells. Frontiers in Molecular Neuroscience. 2020; 13:594319.
.DEK Expression in Breast Cancer Cells Leads to the Alternative Activation of Tumor Associated Macrophages. Cancers. 2020; 12.
.IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models. PloS one. 2020; 15:e0229801.
.2019; 134:4647.
. The Small Molecule IODVA1 Inhibits the Rac Guanine Nucleotide Exchange Factor Vav3 and Overcomes TKI-Resistance in Ph+(BCR-ABL1) B-ALL. Blood.